Irbesartan Pensa (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors on blood vessels, adrenal glands and renal tissue. By preventing angiotensin II from binding, it reduces vasoconstriction, aldosterone release and sympathetic activation, leading to lower systemic vascular resistance, decreased blood pressure, and renal protective effects.

The appropriate dose of Irbesartan Pensa is determined by the prescribing clinician based on the individual’s blood pressure, kidney function and overall health status. Physicians typically start with a low dose and may adjust it to achieve target blood pressure while monitoring safety parameters.

Safety data for Irbesartan during pregnancy are limited, and the drug is generally avoided because it may affect fetal development. Breastfeeding mothers should consult their healthcare provider, as Irbesartan can be excreted in breast milk and the risk to the infant is not well defined.

To order Irbesartan Pensa, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan, as an ARB, offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers, it provides additional renal protection in diabetic patients. Choice of therapy depends on patient tolerance, comorbidities and physician preference.

Irbesartan tablets should be stored at room temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Irbesartan is taken orally as a whole tablet, usually once daily. It can be swallowed with or without food. Patients should follow the prescribing physician’s instructions and not split, crush or chew the tablet unless specifically directed.

The most serious adverse reactions include angio‑edema (swelling of the face, lips, tongue or throat), hyperkalemia (high blood potassium), acute renal impairment and, rarely, liver injury. Patients should seek immediate medical attention if they experience swelling, severe dizziness, or sudden changes in kidney function.

Irbesartan should be avoided in individuals with known hypersensitivity to the drug or any ARB, in patients with severe hepatic impairment, and in pregnant women unless the benefit outweighs the risk. It is also contraindicated in patients taking aliskiren who have diabetes.